diphtheria, tetanus toxoid, pertussis & haemophilus b vaccine (Tetramune, DTP-Hib)

Indications

• active immunization of infants & children 2 months-5 years against diphtheria, tetanus, pertussis & haemophilus b when indications for DPT & HIB coincide

Contraindications

• patients > 7 years of age
• patients with cancer
• immunodeficiency
• children with a history of neurologic disorders
• history of serious adverse reactions to pertussis vaccine
• do not use for treatment of diphtheria, tetanus or pertussis infection
• hypersensitivity to haemophilus b polysaccharide vaccine (thimerosal)

pregnancy-category -

safety in lactation -

Dosage

Children 2 months-6 years (2-3 months recommended)

• 0.5 mL IM on 3 occasions at 4-8 week intervals
• reinforcing dose 1 year after 3rd injection

Injection: 5 mL vials

Pharmacokinetics

elimination: liver

Adverse effects

• convulsions, screaming episodes, malaise, sleepiness, focal neurologic signs, shock, collapse, chills, erythema, induration, rash, urticaria, local tenderness, arthralgias, fever, swelling, warmth, increased risk of haemophilus b infections in the week following vaccination, allergic or anaphylactic reactions (rare)
• all serious adverse reactions must be reported to the FDA

Notes

If adverse reaction occurs, immunization should be completed with diphtheria & tetanus toxoid (dT, Td).

A nodule may be present at the site of injection for a few weeks.

More general terms

• vaccine combination

Additional terms

• Bordetella pertussis
• diphtheria
• Haemophilus influenzae
• tetanus

Components

• tetanus toxoid
• haemophilus b vaccine; HIB vaccine (HibTITER, Hiberix)